fllrn

FLLRN is a biologically active peptide serving as a PAR1-specific antagonist.

YFLLRNP is a biologically active peptide functioning as a partial agonist of PAR-1, selectively activating the G12/13 signaling pathway. At low concentrations, YFLLRNP (60 μM) does not activate Gq or Gi pathways.

TFLLRN-NH2 is a biologically active peptide functioning as a PAR-1 agonist.

TFLLRNPNDK-NH2 is a biologically active peptide and a thrombin receptor activating peptide (TRAP). As a PAR-1 agonist, it reversibly binds to PAR-1, mimicking the 'tethered ligand' created by thrombin through proteolytic substrate cleavage. It also induces increased liquid and protein permeability, similar to thrombin's effect.

Parmodulin 2 (ML 161) is the inhibitor of protease-activated receptor 1 (PAR1)-mediated platelet activation (IC50: 0.26 μM for the inhibition of platelet P-selectin expression on human platelets). It also inhibits thrombin-induced platelet activation.

protease-activated receptor-1 (PAR1) antagonist

RWJ-56110 dihydrochloride is a potent, selective, peptide-mimetic inhibitor of PAR-1 activation and internalization (binding IC50=0.44 μM), showing no effect on PAR-2, PAR-3, or PAR-4. It inhibits the aggregation of human platelets induced by SFLLRN-NH2 (IC50=0.16 μM) and thrombin (IC50=0.34 μM), with high selectivity relative to U46619. RWJ-56110 dihydrochloride also blocks angiogenesis and the formation of new vessels in vivo, and induces cell apoptosis[1][2].

TFLLR-NH2(2TFA) is an agonist of PAR1 (EC50 :1.9 μM).

TFLLR-NH2 2TFA(197794-83-5(free base)) is an agonist of PAR1 (EC50 :1.9 μM).

iso-TRAP-6 (iso-SFLLRN), a hexapeptide derived from the substitution of isoserine for serine, is a protease-activated receptor 1 (PAR1) agonist that activates platelets via PAR-1. iso-TRAP-6 is more resistant to degradation by plasma aminopeptidases than iso-TRAP-6.

TFLLR-NH2 (TFA) is a selective PAR1 agonist with an EC50 of 1.9 μM [EC50: 1.9 μM (PAR1)].